# A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

> **NCT06311721** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 315 (actual)

## Conditions studied

- Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** ABP 234
- **DRUG:** Pembrolizumab (US)
- **DRUG:** Pembrolizumab (EU)

## Key facts

- **NCT ID:** NCT06311721
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2028-01-10
- **Final completion:** 2028-04-24
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06311721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06311721, "A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06311721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*